



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 31/00 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2021/078050

(22) International Filing Date:

11 October 2021 (11.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/090,441 12 October 2020 (12.10.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).(72) Inventors: **DENNIS, Phillip**; AstraZeneca Pharmaceuti-
cals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington,
Delaware 19850-5437 (US). **POOLE, Lynne**; AstraZeneca
UK Limited, 1 Francis Crick Avenue, Cambridge Biomed-
ical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

MAY, Rena; AstraZeneca Pharmaceuticals LP, 1800 Con-
cord Pike, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Milstein Building Granta Park, Cambridge Cam-
bridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ADJUVANT DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF CANCER




FIG. 1

(57) Abstract: The disclosure generally relates to methods for treating cancer in a patient using durvalumab in combination with chemotherapy based on the patient's minimal residual status. Specifically, the disclosure relates to preventing or treating a recurrent tumor in a patient, wherein the patient is minimal residual disease-positive (MRD+), using durvalumab and chemotherapy.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*